Evidence mapPaperPMID 41997994Full record

ArticleScientific reports2026

Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patients.

Sean M Litwin, Ivy V Trinh, Shuangyi Bai, Gilberto Sabino-Santos, Sherry Tong, Amelie E Murrell, Jordan C Scott, Sruti Chandra, Debra H Elliott, Ashley R Smira and 13 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sean M LitwinDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Ivy V TrinhDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Shuangyi BaiPaul G. Allen School for Global Health, Washington State University, Pullman, WA, USA.
Gilberto Sabino-SantosDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Sherry TongDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Amelie E MurrellDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Jordan C ScottDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Sruti ChandraDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Debra H ElliottDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Ashley R SmiraDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Erik L MeyersSection of Infectious Diseases, Tulane University School of Medicine, New Orleans, LA, USA.
Shruti SrinivasanTulane University Newcomb-Tulane College, New Orleans, LA, USA.
Mariza FrancisTulane University Newcomb-Tulane College, New Orleans, LA, USA.
Kelly A GoffDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Sarah E ScheuermannDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Kevin J ZwezdarykDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Nicholas J ManessDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
Amy B KargerDepartment of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA.
John S SchieffelinDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Bronwyn M GunnPaul G. Allen School for Global Health, Washington State University, Pullman, WA, USA.
James E RobinsonDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Crystal Y ZhengSection of Infectious Diseases, Tulane University School of Medicine, New Orleans, LA, USA.
Elizabeth B NortonDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA, 70112, USA. enorton@tulane.edu.

Funding

Tulane National Primate Research CenterP51OD011104 · TULANE UNIVERSITY OF LOUISIANA · 2025 to 2025
$9.3M
NIH HHS P51 OD011104NIH HHS U54CA260581-01
6 · The paper itself

Abstract

People living with HIV infection (PLWH) often have attenuated responses to infections and vaccination. This study aimed to better understand how HIV-associated inflammation and chronic T-cell activation influenced the immune responses to mRNA vaccination or neutralization assay analyses. PLWH on ART or healthy donor controls were analyzed using systems serology and viral T-cell phenotyping to Spike or HIV-1 Gag peptide stimulation after primary mRNA COVID-19 vaccination. Neutralization assays using a lentiviral pseudovirus construct were compromised by the presence of integrase strand transfer inhibitor (INSTI) drugs in plasma from HIV + subjects taking certain ART. This combination of lentiviral pseudovirus reporter assays and INSTIs led to false positive neutralization results. Spike-specific IgG1, IgG3, IgA1, IgA2, and antibody-dependent cellular phagocytosis (ADCP) were altered post-vaccination in PLWH compared to controls. Network and multivariate analyses revealed post-vaccination outcomes were strongly correlated to CD4 immunodeficiency and Gag-specific T-cells, including effector CD8 T-cells and Th1 CD4 T-cells. Given the growing use of pseudovirus neutralization assays for serological evaluation and mRNA technology in novel vaccines that could be recommended for PLWH Pseudovirus neutralization assays need to be carefully selected to prevent ART drugs in patient samples from impacting results. Spike-specific antibody and CD4 T-cell phenotypes are influenced by both CD4 immunodeficiency and Gag-specific T-cell effector populations. This work has clinical relevance beyond COVID, with future considerations of pseudovirus assay evaluations and mRNA vaccine design for chronically infected hosts.

Indexed as

Anti-Retroviral AgentsCOVID-19 Vaccinesgag Gene Products, Human Immunodeficiency VirusHIV InfectionsT-LymphocytesAdultAntibodies, NeutralizingCD4-Positive T-LymphocytesCOVID-19FemaleHIV-1HumansMaleMiddle AgedmRNA VaccinesNeutralization TestsAntibodies, NeutralizingAnti-Retroviral AgentsCOVID-19 Vaccinesgag Gene Products, Human Immunodeficiency VirusmRNA VaccinesAIDS/HIVImmunoglobulinsImmunologyT-cellsVaccinesVirology

Identifiers

PMID41997994
PMCPMC13249817

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.